Life Expectancy with MELD Score 31: Prognosis & Transplant Considerations

The Model for End‑Stage Liver Disease (MELD) score predicts 3‑month mortality in cirrhosis. A MELD of 31 indicates advanced liver failure and high short‑term mortality.

Survival Estimates

• Median survival without transplant: ~3 months (50% mortality at 3 months).
• Individual outcomes vary widely based on etiology (alcohol, HCV, NASH, etc.), comorbidities, frailty, and acute‑on‑chronic liver failure (ACLF) triggers.

Key Determinants of Outcome

• MELD trajectory (rising vs. stable)
• Presence of ACLF (organ failures)
• Nutritional status, sarcopenia
• Infections, hepatic encephalopathy, variceal bleeding
• Access to liver transplantation

Transplant: The Definitive Therapy

• MELD ≥15 generally warrants transplant evaluation.
• At MELD 31, transplant offers dramatic survival benefit: 1‑year post‑transplant survival >90%.
• Barriers: donor shortage, medical/surgical contraindications, psychosocial factors.

Supportive Care While Waiting

• Diuretics for ascites, lactulose/rifaximin for encephalopathy
• Beta‑blockers for variceal prophylaxis
• Nutrition: high‑protein, nocturnal snacks; avoid salt
• Vaccinations (pneumococcal, influenza, hepatitis A/B)
• Abstinence from alcohol; manage metabolic comorbidities

Shared Decision‑Making

Discuss goals of care, transplant candidacy, and palliative options early. Palliative care integration improves quality of life regardless of transplant status.